Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert Christopher Cook is Chief Operating& Legal Officer at Filana Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 18, 2026, each linked to the official Form 4.
Chief Operating& Legal Officer
Disclosures on record
1
Companies involved
1
1 purchase disclosed. $1,000 placed after each of the 1 purchases disclosed since 2025-11-20 would be worth $1K today ($1K put in); the same in the S&P 500 (SPY): $1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.8 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Nov 16, 2026Bought~$56Kdisclosed Nov 18
DetailsOfficial recordAs of the latest filing on , Robert Christopher Cook reported holding 135,300 shares of Filana Therapeutics (FLNA), worth about $76K at the last close of $1 (Nov 19, 2026). In the last 12 months, Robert Christopher Cook bought $56K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Filana Therapeutics FLNA | 135,300 | 135K direct | $1 | $76K | Nov 16, 2026 |
Is this Robert Christopher Cook’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Robert Christopher Cook bought shares on the open market in 2026.
Robert Christopher Cook reported 1 open-market purchase and 0 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $56K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 16, 2026, Robert Christopher Cook reported holding 135,300 shares of Filana Therapeutics (FLNA). At the last close of $1 on Nov 19, 2026, that is about $76K. This is the stake disclosed in filings, not a net worth.
No public filing gives Robert Christopher Cook's net worth. What SEC Form 4 shows is the stock stake: 135,300 shares of Filana Therapeutics (FLNA), about $76K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
In SEC filings of the last 12 months, Robert Christopher Cook reported 1 open-market purchase worth $56K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Robert Christopher Cook bought shares on the open market in 2026.
In SEC filings since 2026: the latest open-market purchase is from 2026; no open-market sale is on record.
Filana Therapeutics (FLNA), from 2026 to 2026: 1 purchase and 0 sales.
Robert Christopher Cook reported 1 open-market purchase and 0 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.